| Association of Receipt of a Housing Voucher With Subsequent Hospital Utilization and Spending CE Pollack, AL Blackford, S Du, S Deluca, RLJ Thornton, B Herring JAMA 322 (21), 2115-2124, 2019 | 38 | 2019 |
| Health Care Spending by Enrollees With Substance Use and Mental Health Disorders in High-Deductible Health Plans vs Traditional Plans MD Eisenberg, S Du, AP Sen, A Kennedy-Hendricks, CL Barry JAMA Psychiatry, 2020 | 11 | 2020 |
| Experiment to decrease neighborhood poverty had limited effects on emergency department use CE Pollack, S Du, AL Blackford, B Herring Health Affairs 38 (9), 1442-1450, 2019 | 10 | 2019 |
| Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A … B Lowentritt, D Pilon, D Waters, C Rossi, E Muser, S Kurteva, A Shah, ... Urologic Oncology: Seminars and Original Investigations 41 (5), 252. e19-252 …, 2023 | 3 | 2023 |
| Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib+ Checkpoint Inhibitor Y Zakharia, L Huynh, S Du, R Chang, S Pi, S Sundaresan, MS Duh, ... Clinical genitourinary cancer 21 (5), e343-e351, 2023 | 1 | 2023 |
| Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization J Hwee, L Huynh, S Du, N Kwon, RW Jakes, R Alfonso-Cristancho, ... Annals of Allergy, Asthma & Immunology 130 (6), 768-775, 2023 | 1 | 2023 |
| MP29-14 PROSTATE-SPECIFIC ANTIGEN RESPONSE AND TIME-TO-CASTRATION RESISTANCE AMONG PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER INITIATED ON APALUTAMIDE … B Lowentritt, S Du, C Rossi, F Kinkead, D Waters, B Moore, P Lefebvre, ... The Journal of Urology 209 (Supplement 4), e387, 2023 | 1 | 2023 |
| Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ … BH Lowentritt, C Rossi, S Du, E Muser, F Kinkead, D Waters, P Lefebvre, ... Journal of Clinical Oncology 41 (6_suppl), 65-65, 2023 | 1 | 2023 |
| Health Plan Choice and the Valuation of Plan Attributes in the ACA Marketplaces S Du 2018 Annual Research Meeting, 2018 | 1 | 2018 |
| REAL-WORLD CLINICAL OUTCOMES OF MEDICARE PATIENTS WITH HIGH-RISK LOCALIZED PROSTATE CANCER TREATED WITH EXTERNAL BEAM RADIATION THERAPY OR RADICAL PROSTATECTOMY STRATIFIED BY … L Karsh, S Du, J He, E Muser, N Shore Urologic Oncology: Seminars and Original Investigations 42, S16, 2024 | | 2024 |
| Real-world survival of men with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or enzalutamide (ENZ) in an oncology database: ROME Study. MA Bilen, S Du, I Khilfeh, C Rossi, J Korsiak, A Rahman, P Lefebvre, ... Journal of Clinical Oncology 42 (4_suppl), 57-57, 2024 | | 2024 |
| Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS). BL Maughan, S Mundle, M Nematian-Samani, X Wang, S Du, Y Liu, ... Journal of Clinical Oncology 42 (4_suppl), 65-65, 2024 | | 2024 |
| Prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or abiraterone acetate (ABI … GA Brown, I Khilfeh, S Du, C Rossi, L Diaz, F Kinkead, E Muser, J Korsiak, ... Journal of Clinical Oncology 42 (4_suppl), 53-53, 2024 | | 2024 |
| Analysis of real-world survival for patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or abiraterone acetate (ABI) in an … MA Bilen, I Khilfeh, C Rossi, S Du, J Korsiak, A Rahman, P Lefebvre, ... Journal of Clinical Oncology 42 (4_suppl), 58-58, 2024 | | 2024 |
| Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or … BH Lowentritt, S Du, D Pilon, I Khilfeh, E Muser, C Rossi, F Kinkead, ... Journal of Clinical Oncology 42 (4_suppl), 51-51, 2024 | | 2024 |
| Description et fardeau de la granulomatose éosinophilique avec polyangéite: une étude rétrospective européenne S Hu, RW Jakes, N Kwon, L Huynh, J Hwee, B Lee, R Alfonso-Cristancho, ... La Revue de Médecine Interne 44, A161, 2023 | | 2023 |
| CO27 Real-World Treatment Response and Persistence Among Black and Non-Black Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with Apalutamide in a Urology … B Lowentritt, S Du, C Rossi, F Kinkead, B Moore, P Lefebvre, D Pilon, ... Value in Health 26 (6), S19, 2023 | | 2023 |
| EE186 Healthcare Utilization of Patients with Hypereosinophilic Syndrome in Europe J Hwee, N Kwon, R Alfonso-Cristancho, L Baylis, G Requena, S Du, ... Value in Health 26 (6), S93, 2023 | | 2023 |
| Real-world prostate-specific antigen (PSA) response and disease progression among patients with non-metastatic castration-resistant prostate cancer (nmCRPC) initiated on … BH Lowentritt, S Du, C Rossi, F Kinkead, D Waters, B Moore, P Lefebvre, ... Journal of Clinical Oncology 41 (6_suppl), 69-69, 2023 | | 2023 |
| Real-world clinical outcomes of patients with localized prostate cancer (LPC) treated with external beam radiation therapy (EBRT). LI Karsh, S Du, J He, D Waters, E Muser, ND Shore Journal of Clinical Oncology 41 (6_suppl), 330-330, 2023 | | 2023 |
Craig PollackJohns Hopkins School of MedicineVerified email at jhmi.edu
